The Establishment and Maintenance of a Comprehensive Thoracic Tumor Data Registry and Bioreceptor
Aims: The purpose of this database is to allow researchers to review and compare medical information including medical history, symptoms, medical test results, treatments, and complications that people with thoracic tumors may have. Another purpose of this study is to collect leftover tissue obtained during thoracic surgery or diagnostic tests. Research testing of this tissue may help to determine the changes which lead to the development and/or spread of cancer. This information may help to develop new kinds of diagnostic tests and treatment for thoracic cancer.
Diagnosis: Thoracic Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH98-136
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research coordinator Kanwal Zeeshan at 847.570.1697
Open to Enrollment: Yes
LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-
Small Cell Lung Cancer
Aims: The purpose of this study screening step is to perform genetic tests on your tumor sample for certain features that investigational targeted agents used in this study are specifically designed to work against. Then the purpose is to assign you to a treatment sub-study that is chosen based on the results (genes and proteins called "biomarkers") of this genetic testing on your tumor sample. This study related "research test" will be done in a special lab. The system of assigning a treatment sub-study based on genetic testing of cancer is investigational; in squamous cell lung cancer patients, we don’t know whether testing can identify patients who will or will not benefit from treatment.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH19-106
Sponsor: Southwest Oncology Group
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
E4512: Testing the Addition of Drug Crizotinib After Surgery to Remove ALK-Positive Non-Small Cell Lung Cancer: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Aims: The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI(R)), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. In addition, crizotinib may help prevent your cancer from returning, but it could also cause side effects. This research study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH15-121
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact Michele Britto at 847.570.2109
Open to Enrollment: Yes
A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Aims: The purpose of this research study is to determine if patients with Non-Small Cell Lung Cancer (NSCLC) have a mutation (abnormal change) in the DNA or their tumor and if so, which one. The genetic mutations which are being assessed are EGFR, ALK, and dPD-L1. Not all lung tumors have changes in genes. The study will lead into two optional treatment trials that will use specific drugs to target these genes as well as tumors without mutations. Tissue from the tumor removed at the time of surgery is sent to a national laboratory to be analyzed and compared to local results.
Diagnosis: Non-Small Cell Lung Cancer (NSCLC) Stage IB, II, IIIA
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH15-122
Sponsor: Alliance
Contact: Interested patients should contact Michele Britto at 847.570.2109
Open to Enrollment: Yes
A081801: Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO (ACCIO)
Aims: The purpose is to see if adding the drug pembrolizumab to standard therapy will lower the change of lung cancer coming back.
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH20-364
Sponsor: Alliance
Contact: Interested patients should contact Michele Britto at 847.570.2109
Open to Enrollment: Yes
Best Practice in VATS Lobectomy and Segmentectomy for Lung Cancer: A Prospective, Observational, Quality Improvement Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)
Aims: This is a multi-center study that will be conducted at seven sites. The purpose of this study is to establish a database for doing data and cost analysis of the workup, early treatment and follow-up of patients who have VATS lobectomy or segmentectomy for lung cancer.
Diagnosis: Lung Cancer
Principal Investigator: Seth Krantz, MD
IRB Approval Number: EH13-155
Sponsor: Ethicon Endo-Surgery
Contact: Interested participants may contact Kanwal Zeesha, MBBS, CCRP at 847.570.1697, kzeesha@northshore.org
Open to Enrollment: Yes
NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Aims: The purpose of this research study is to see if the addition of atezolizumab can lower the chance of small cell lung cancer from growing or spreading.
Diagnosis: Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH20-114
Sponsor: NRG Oncology
Contact: Interested patients should contact Michele Britto at 847.570.2109
Open to Enrollment: Yes
Prospective Registrational Trial to Define Real World Outcomes of Patients with Completely Resected Stage I or IIA Non-squamous Non-Small Cell Lung Cancer (NSCLC) Identified as High, Intermediate, or Low Risk by a 14-Gene Prognostic Assay, DetermaRXTM, being Considered for Adjuvant Platinum-based chemotherapy or other Adjuvant therapy versus Observation Or Predictive Assay for Decision Making in Adjuvant Therapy (PADMA)
Aims: The purpose of this research study is collect information about patients who undergo testing with DetermaRX and their outcomes..
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Carolina Soto Chervin
IRB Approval Number: EH20-077
Sponsor: Oncocyte Corporation
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
EA5181: A Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Aims: The purpose is to see if addinb the drug, durvalumab, during chemotherapy/radiation will prevent the tumor from coming back.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH20-371
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
AbbVie M14-239: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-MET+ Non-Small Call Lung Cancer
Aims: The purpose of this research study is to see the good/bad effects of Vedotin and see if it prevents the lung cancer from getting worse.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH20-055
Sponsor: AbbVie, Inc.
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
PrECOG 0506: DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma- A phase 3 Randomised trial
Aims: The purpose of this research study is to see the good/bad effects of adding durvalumab to standard chemotherapy for mesothelioma.
Diagnosis: mesothelioma
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH21-309
Sponsor: PrECOG, LLC
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
SWOG 1900E: A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Aims: The purpose of this research study is to see the good/bad effects of Sotorasib and see if it prevents the lung cancer from getting worse.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH21-301
Sponsor: Southwest Oncology Group
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes